Fitch, James, 1622-1702, autographed letter signed to John Winthrop; Saybrooke [sic], Conn., 1 side (2 pages), 1652 April

Correspondence requesting medicines from Winthrop for his stomach ailment, and for a neighbor who was suffering from edema.

Stone, Sam, 1602-1663, autographed letter signed to John Winthrop; Hartford, 1 side (3 pages), 1652 February 1652

Correspondence seeking advice from Winthrop about his 23-week-old son, who was suffering from jaundice and a cough. Stone writes the course of treatment for the infant, on the advice of a Mrs. Hooker, had included barbaric bark boiled in beer with saffron twice daily, as well as turmeric. He also administered Winthrop's purging powder, and Stone asks if he should continue giving the powder and at what dose, and if there is any other medicines Winthrop would prescribe.

Account books of Thomas Cradock, 1786-1818 (inclusive)

Account books listing patients, medicines administered, and fees charged by Dr. Thomas Cradock (1752-1821), primarily in Maryland, from 1786 to 1818. In addition to recording names, Cradock occasionally noted demographic information, the patient's location, or their occupation: from 1813 to 1816, he treated Richard Gent, a free African-American man; in 1813, he attended to John Bell, who lived in the Foggy Bottom neighborhood of Washington, D.C. Cradock further noted if the patient was a slave and the name of his or her owner. He would also administer care on behalf of corporate entities, such as Powhatan Factory, which apparently refused him payment. He also sometimes included a diagnosis: in the cases of a Mr. Rowles and Mrs. Violet West, he administered unspecified medicines for gonorrhea at a cost of ten dollars. Commonly prescribed drugs included emetics, cathartics, and anodynes. Cradock also provided smallpox vaccination for his patients. He accepted both cash and payment-in-kind. Tipped into the first volume is an envelope containing a letter from the Medical and Chirurgical Faculty of Maryland to Mrs. Thomas Craddock in 1899 requesting a loan of portrait of Dr. Thomas Craddock [sic]. The three volumes also each contain an index to patient names.

Account books of William Aspinwall, 1776-1812 (inclusive)

Two account books containing entries noting patients visited, fees charged, and small accounts of Dr. William Aspinwall (1743-1823) in Boston and Brookline, Massachusetts, from 1776 to 1812. He includes sections for "Women's Accounts" with charges generally rendered to their husbands or other male relatives. There is also an entry charging the town of Cambridge, Massachusetts, four dollars and fifty cents for medicines and attendance to a boy who contracted smallpox.

Account book of Daniel Brigham, 1781-1798 (inclusive)

Account book maintained by Dr. Daniel Brigham (1760-1830) for services provided to approximately 180 patients, treated primarily in Northborough, Westborough, and Marlborough, Massachusetts, and surrounding towns between 1781 and 1798. The ledger details the charges for his visits to patients and medicines he prescribed. Common charges included one shilling, four pence for Brigham to visit and administer an emetic or cathartic to a patient. A visit and bloodletting by Brigham cost one patient two shillings, eight pence. He charged six shillings to amputate a toe, and eight pence to extract a tooth. Includes an index to patient names. The ledger also records household and miscellaneous expenses of Brigham.

William Blair Townsend letter and receipt books, 1743-1805, bulk 1744-1777

The collection consists of two volumes, which date from 1743 to 1805, spanning his whole career as a merchant. Volume one is a letter book containing Townsend's business correspondence from November 23, 1743 to December 12, 1774. Most of the letters were written to American (many in North Carolina) and British (predominately in London) merchants. His earliest letters document his efforts to establish himself as a trader. Over time his letters turn to illustrate the common problems faced by many merchants: damaged goods, overpriced goods, embargos, and high freight costs. Particularly enlightening are his comments on the challenges of doing business throughout the French and Indian War and the years leading up to the American Revolution. He most frequently corresponded with London merchants Champion & Hayley, Lane & Booth, Lane Son & Fraser, Harrison & Ansley, and Leeds merchant Samuel Elam. In addition he frequently corresponded with Eliakim Palmer, colonial agent and merchant in London, as well as Dr. Walley Chauncy of North Carolina. He dealt in a wide variety of goods including molasses, rum, tar, medicines, pitch, saddles, tallow, hides, skins, pickled beef and pork, and wine. The letters also document Townsend's involvement in the slave trade through his occasional purchases of slaves.

Account books of Sylvester Woodbridge, 1792-1826 (inclusive)

Consists of seven account books kept by Dr. Sylvester Woodbridge (1754-1824) from 1792 until his death containing entries that record charges for medical visits and administration of medicines, and sales of sundry and grocery items, as well as occasional personal notes and the names of Woodbridge's apprentices and their participation in his Southampton, Massachusetts, medical practice. Woodbridge's methods of treatment were typical for the era: he most commonly prescribed vomits and purgatives for patients. Volume 6 contains loose pages and letterbooks tucked in related to accounting and to the amount and type of wood Woodbridge was buying for his house, and papers dated after his death.

Cases copied by James Lloyd from Mr. Steed, apothecary in Guy's Hospital, London, 1751-1787 (inclusive)

Contains medical cases copied by James Lloyd (1728-1810), primarily between 1751 and 1754, from Mr. Steed, an apothecary at Guy's Hospital in London, England. The volume has additional medical cases dating from 1780 to 1787. Lloyd transcribed the names, ages, and symptoms of the patients, as well as the medicines and medical care delivered to them. The volume is divided into chapters based on the type of case, which included vision loss; fluor albus, or leucorrhoea; diabetes; and dysentery. There is also a letter pasted into the volume addressed to Dr. Brigham of the Boston Medical Library Association from Lloyd's great-grandson, dated 4 November 1887.

Student notebook of Benjamin Waterhouse: 1776

Volume containing notes taken in 1776 by Benjamin Waterhouse (1754-1846) on medical lectures given in Scotland by University of Edinburgh Professor Andrew Duncan (1744-1828). The lectures focused on pathology, with attention given to secretion, absorption, nutrition, excretion, circulation, and respiration. There are also notes on common medicines and their indications and contraindications, such as emetics, cathartics, diaphoretics, and diuretics.

Estatinas e risco de diabetes : revisão sistemática

Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2014

Mycophenolatemofetil in non-renal systemiclupuserythematosusmanifestations

Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2014

Patenting Strategies of the EU Pharmaceutical Industry -Crossroad between Patent Law and Competition Policy. Research Papers in Law, 1/2011

From the Introduction. The pharmaceutical sector inquiry carried out by the European Commission in 2008 provides a useful framework for assessing the relationship between the patent system on the one hand and competition policy and law on the other hand. The pharmaceutical market is not only specifically regulated. It is also influenced by the special characteristics of the patent system which enables pharmaceutical companies engaged in research activities to enter into additional arrangements to cope with the competitive pressures of early patent application and the delays in drug approval. Patents appear difficult to reconcile with the need for sufficient and adequate access to medicines, which is why competition expectations imposed on the pharmaceutical sector are very high. The patent system and competition law are interacting components of the market, into which they must both be integrated. This can result in competition law taking a very strict view on the pharmaceutical industry by establishing strict functional performance standards for the reliance on intellectual property rights protection granted by patent law. This is in particular because in this sector the potential welfare losses are not likely to be of only monetary nature. In brief, the more inefficiencies the patent system produces, the greater the risk of an expansive application of competition law in this field. The aim of the present study is to offer a critical and objective view on the use or abuse of patents and defensive strategies in the pharmaceutical industry. It shall also seek to establish whether patents as presently regulated offer an appropriate degree of protection of intellectual property held by the economic operators in the pharmaceutical sector and whether there is a need or, for that matter, scope for improvement. A useful starting point for the present study is provided by the pharmaceutical sector competition inquiry (hereafter “the sector inquiry”) carried out by the European Commission during the first half of 2008. On 8 July 2008, the Commission adopted its Final Report pursuant to Article 17 of Regulation 1/2003 EC, revealing a series of “antitrust shortcomings” that would require further investigation1.

Transatlantic MRAs: Lessons for TTIP? CEPS Special Report No. 101/March 2015

It is striking that there is little or no mention in the TTIP debate so far of the US-EU Mutual Recognition Agreement (MRA) concluded in 1998. At the time, expectations of the gains from the MRA were high. One should expect the MRA to be instructive for TTIP and entail some lessons to be learned for today’s attempt to lower technical barriers to trade (TBTs) across the North Atlantic. We offer an analysis of the 1998 MRA, the difficulties in the prior negotiations and those during the implementation phase, the subsequent and present status of sectoral approaches. The MRA experience revealed clearly how difficult it is to accomplish the acceptance of all relevant aspects of conformity assessment of the trading partner for the mere purpose of testing and certifying export goods on the requirements of the importing economy. The MRA has succeeded only in a few sectors. However, the ambition in TTIP with respect to TBTs is said to go so much further. It is therefore important for all those involved or interested in TTIP to learn the lessons of this early exercise in lowering TBT costs. This paper reaches two main conclusions: i) the US-EU MRA was only partially successful and only for some one-fifth of the export flows at the time: a disappointing outcome and a far cry from the expectations of business and political leaders; and ii) the EU’s attempt to ‘balance’ the negotiations in 1995 by bringing in three relatively competitive sectors did not work out – it was precisely there that problems accumulated. It is critical that domestic regulators must be satisfied during and after the negotiations that their pursuit of health, safety, environment and consumer protection objectives will not be watered down in any way. Lessons drawn include, among others: MRAs are not about regulatory change (by definition), but if initial regulatory cleavages between trading partners are too wide, conditions become so restrictive that parties may regard them as a denial of the very purpose of the MRA. There are incentives to opt for alternatives in the market for the formalised designation of conformity assessment bodies in the MRA and these are often cheaper and faster, while equally qualified. Even in heavily regulated sectors such as medicines and medical devices, the narrow MRA has been superseded by near-global forms of effective cost-reducing cooperative (i.e. not treaty-based) regulatory alignment, a confirmation of the OECD approach that governments should think in terms of an entire spectrum of forms of regulatory cooperation.